Compare BHM & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHM | NSRX |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.5M | 38.9M |
| IPO Year | 2022 | 2024 |
| Metric | BHM | NSRX |
|---|---|---|
| Price | $7.93 | $3.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $15.00 | ★ $19.67 |
| AVG Volume (30 Days) | 1.7K | ★ 9.0K |
| Earning Date | 01-01-0001 | 03-25-2026 |
| Dividend Yield | ★ 4.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.88 | N/A |
| 52 Week Low | $8.02 | $1.98 |
| 52 Week High | $13.30 | $9.50 |
| Indicator | BHM | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 50.48 |
| Support Level | N/A | $2.97 |
| Resistance Level | $8.97 | $3.60 |
| Average True Range (ATR) | 0.23 | 0.27 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 1.90 | 68.73 |
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.